



# Generation of gene-engineered hematopoietic stem cells

## CliniMACS Prodigy® Hematopoietic Stem Cell Engineering System

### Application

The CliniMACS Prodigy® Hematopoietic Stem Cell Engineering System allows fully automated transduction of human CD34<sup>+</sup> cells from patient material for the generation of gene-engineered hematopoietic stem cells (HSCs).

This application sheet gives an overview of the process, the specifications, and materials needed. In addition, it elucidates the setup of the CliniMACS Prodigy Tubing Set (TS) 520 and the performance data.

### Specifications


<b>Cellular starting material:</b>	CD34 <sup>+</sup> cells, e.g., enriched from mobilized leukapheresis
<b>Starting cell number:</b>	at least 2×10 <sup>7</sup> cells
<b>Starting sample volume:</b>	40–250 mL
<b>Final product:</b>	gene-engineered CD34 <sup>+</sup> cells
<b>Final product volume:</b>	100 mL
<b>Process time:</b>	2–3 days

Products	Amount required*
CliniMACS Prodigy® Instrument	1 piece
CliniMACS Prodigy TS 520	1 set
HSC-Brew GMP Medium	2 L
MACS® GMP Recombinant Human Flt3-Ligand (100 µg)	1 vial
MACS GMP Recombinant Human SCF (100 µg)	1 vial
MACS GMP Recombinant Human TPO (50 µg)	1 vial
MACS GMP Recombinant Human IL-3 (25 µg)	1 vial
1 m Tube Extension	1 piece
3-way Tube Adapter	2 pieces

Additional materials	Amount required*
Transfer bag 150 mL	3 bags
Transfer bag 600 mL	1 bag
Luer/Spike Interconnector	4 pieces
Formulation solution (physiological sodium chloride solution with 0.5% (w/v) human serum albumin)	1 L
Lentiviral vector	MOI depends on the used vector


\*Amount is given for the one-hit lentiviral transduction of 1×10<sup>8</sup> cells in 100 mL. Please discuss your specific requirements with your Miltenyi Biotec representative.

## Process overview for HSC engineering




\*The duration of the HSC engineering process depends on the number of transduction cycles


## Principle of the HSC engineering process on the CliniMACS Prodigy®



## CliniMACS Prodigy TS 520 setup for HSC engineering



## Performance data



Human CD34<sup>+</sup> cells enriched from eight mobilized leukapheresis products were transferred into HSC-Brew GMP Medium supplemented with MACS<sup>®</sup> GMP Recombinant Human Flt3-Ligand, SCF, TPO, and IL-3 (day 0) and transduced with lentiviral vector encoding GFP (MOI 100) on day 1 using the CliniMACS Prodigy<sup>®</sup> HSC Engineering System. The same experiment was performed manually following a standard protocol using 24-well plates. **(A)** On day 2, similar cell recovery was detected when using the CliniMACS Prodigy HSC Engineering System and manual handling. **(B)** Harvested gene-engineered CD34<sup>+</sup> cells were further cultured manually in 96-well plates and transduction efficiency was measured on day 5. Transduction efficiency of CD34<sup>+</sup> cells processed with the CliniMACS Prodigy was comparable to that of cells processed manually.



**Miltenyi Biotec B.V. & Co. KG** | Phone +49 2204 8306-0 | Fax +49 2204 85197 | [macs@miltenyibiotec.de](mailto:macs@miltenyibiotec.de) | [www.miltenyibiotec.com](http://www.miltenyibiotec.com)  
 Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS<sup>®</sup> GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS<sup>®</sup> System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. All other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS, CliniMACS Prodigy, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.